In short
Venetoclax in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are ineligible for intensive chemotherapy and who have no other suitable treatment option and are not eligible to participate in a clinical study for their serious condition.
For any questions, please contact be.mnp@abbvie.com
Information sheet
Member login required
This content is part of our learning materials for our members. Login or see our membership information